Abstract 445P
Background
Colorectal cancer (CRC) patients treated with curative intended surgery undergo 5-FU continuous infusion based chemotherapy using totally implantable central venous port system (TICVPS) in case of high-risk of recurrence. Approximately 30% patients relapse after the completion of therapy, especially within 2 years. Hence, many of high-risk CRC patients keep the TICVPS during 6-24 months after treatment, with regular intervals of TICVPS flushing. The manufacturer recommends monthly flushing for maintain TICVPS, however the interval of flushing lacks scientific evidence. The aim of this study is to investigate whether the extended maintenance intervals is safe and feasible.
Methods
A retrospective cohort was conducted in CRC patients who underwent curative intended surgery and perioperative chemotherapy using TICVPS between 2010 and 2017. Patient were enrolled if TICVPS was maintained at least 6 months with 3-month interval flushing using heparin, while patient who were recurred within 1 month, removed TICVPS within 6 months without definitive causes, or violation of flushing interval were excluded. The primary end points were the functional TICVPS maintenance rate.
Results
A total of 214 CRC patients underwent curative intended treatments during the study period. Among them, 6 patients (early recurrence within 1 month) and 54 patients (violation of flushing interval) were excluded, finally 154 patients were analyzed. Mean flushing interval was 98.4 days. At the Dec 2018, 35 patients kept the TICVPS, 92 were planned removal, and 25 were reused the TICVPS, while two patients had to unexpectedly remove due to TICVPS site infection and pain. Thus, the functional TICVPS maintenance rate was 98.8%. 38 patients were relapsed and 30 were treated with intravenous chemotherapy. Among them, 25 patients (83.3%) were reused the existing TICVPS without re-insertion procedure.
Conclusions
Our study demonstrated that 3-month interval flushing is safe and feasible in CRC patients. Extended time interval up to 3 months might be considered because it is compatible with CRC surveillance visit schedules and convenient for patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract